1. Immune-related adverse events linked to improved pembrolizumab outcomes in urothelial carcinoma  Urology Times
  2. Immune-Related Adverse Effects Linked to Longer Survival With Pembrolizumab in Metastatic Urothelial Carcinoma  OncLive
  3. View Full coverage on Google News
Immune-related adverse events may be a prognostic marker for improved survival and progression-free outcomes with pembrolizumab in patients with metastatic urothelial carcinoma.Immune-related adverse events may be a prognostic marker for improved survival and progression-free outcomes with pembrolizumab in patients with metastatic urothelial carcinoma.

Immune-related adverse events linked to improved pembrolizumab outcomes in urothelial carcinoma